Drugs / trisodium citrate
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00695617 | Jul 2008 → Dec 2009 | liver failure | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01962116 | Jun 2013 → Apr 2016 | — | Centre Hospitalier Universitaire Dijon | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02563041 | Jul 2012 → Jul 2014 | prosthesis-related infectious disease | Catholic University of Pelotas | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07618858 | Jun → Dec 2026 expected | end stage renal failure | University Medical Centre Ljubljana | Not yet recruiting | No outcome recorded |
| — | NCT04139525 | Sep 2020 → Dec 2022 | end stage renal failure | Marija Malgaj Vrečko | Unknown | No outcome recorded |
| — | NCT03419923 | Sep 2017 → Mar 2019 | — | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| — | NCT01839578 | May 2013 → Nov 2014 | infectious disease with sepsis | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT07518303 Comparator | Jun 2026 → Jun 2028 expected | acute kidney injury, infectious disease with sepsis | Jianfeng Xie | Not yet recruiting | No outcome recorded |
| — | NCT01689753 Comparator | Mar 2009 → Apr 2010 | — | Erasme University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trisodium citrate | “4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according...” NCT03419923 ↗8“Regional citrate anticoagulation using 8% trisodium citrate infusion during postdilution hemodiafiltration with calcium substitution adjusted according to ionized calcium levels.” NCT07618858 ↗ “Citrate (3% or 4% trisodium citrate solution) is a regional anticoagulant that chelates ionized calcium in the extracorporeal circuit, thereby inhibiting the coagulation cascade.” NCT07518303 ↗ “A catheter lock solution composed of trisodium citrate at 4% will be compared to unfractionated heparin at a concentration of 5,000 IU/mL.” PMID 25409678 ↗ Nov 2014 “4% trisodium citrate solution” NCT01839578 ↗ “30% trisodium citrate” NCT02563041 ↗ |
| Known as | Citrate | “Citrate (3% or 4% trisodium citrate solution) is a regional anticoagulant that chelates ionized calcium in the extracorporeal circuit, thereby inhibiting the coagulation cascade.” NCT07518303 ↗ |
| Action | Inhibit | “Citrate (3% or 4% trisodium citrate solution) is a regional anticoagulant that chelates ionized calcium in the extracorporeal circuit, thereby inhibiting the coagulation cascade.” NCT07518303 ↗ |
| Route | Other | “A catheter lock solution composed of trisodium citrate at 4%” PMID 25409678 ↗ Nov 2014 |